Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R, Cameron D.
Coleman RE, et al. Among authors: marshall h.
J Bone Oncol. 2018 Sep 27;13:123-135. doi: 10.1016/j.jbo.2018.09.008. eCollection 2018 Nov.
J Bone Oncol. 2018.
PMID: 30591866
Free PMC article.